Blog
Blog
The CI Capacity Squeeze, and Three Questions To Ask Before 2027 Planning
Every year the competitive field gets more crowded: more assets, more readouts, more congress abstracts, more competitor moves to track. Products are more complex too, from special distribution to patient and healthcare professional (HCP) education requirements. And every year, pharma competitive intelligence (CI) teams are asked to cover more of it. What’s changed is that resources aren’t keeping up.
Filter posts by:
Blog
The CI Capacity Squeeze, and Three Questions To Ask Before 2027 Planning
Every year the competitive field gets more crowded: more assets, more readouts, more congress abstracts, more competitor moves to track. Products are more complex too, from special distribution to patient and healthcare professional (HCP) education requirements. And every year, pharma competitive...
Blog
CNS Innovation: What It Takes to Win
Scientific progress is expanding what central nervous system (CNS) therapies can target and deliver. Whether those advances become viable treatments depends on four conditions: meaningful unmet need, a justified treatment burden, a feasible modality and delivery approach, and a workable path...
Blog
How the CMS GENEROUS Model Changes Medicaid Drug Pricing
The CMS GENEROUS model is designed to align Medicaid pricing to an international benchmark through agreements with manufacturers and states. Its value depends on the balance between lower net prices, standardized coverage policies, and existing rebate arrangements, alongside manufacturers’ incentives to...
Blog
Beyond the ICD Code: Why Patient Finding Must Lead to Commercial Action
For years, the life sciences industry has invested heavily in finding patients earlier, more accurately, and at greater scale. As data sources expand and machine learning models improve, patient-finding programs have become more sophisticated. A new generation of AI capabilities now...
Blog
What NRDL 2025 Outcomes Mean for Drug Pricing and Market Access in China
China's reimbursement environment changed with the introduction of the NRDL value rating framework in 2023 and the Commercial Insurance Innovative Drug List (CIIDL) in 2025. NRDL 2025 outcomes show that payers continue rewarding breakthrough therapies, comparative evidence, and treatments for unmet...
Blog
From Research Delivery to Decision Orchestration: The Next Evolution of PMR
Primary market research (PMR) has long been a trusted advisor to brand teams, helping organizations understand customers, test assumptions, and reduce uncertainty in critical business decisions. Over the past decade, however, many PMR organizations have been asked to do more with...
